MINNEAPOLIS (April 19, 2017) – Tomorrow, OneOme’s director of medical affairs Josiah Allen will join the Minnesota Health Care Roundtable on precision medicine. The panel, which includes local leaders in the field, takes place on Thursday, April 20, from 1 to 4 p.m. at the Downtown Minneapolis Hilton and Towers. The roundtable discussion aims to explore how technological and policy advancements can promote more precise medical treatments to improve health.
During the event, Allen will discuss how pharmacogenomics will contribute to the future of medicine. OneOme is in a postion to help lead the advancement of pharmacogenomics, which combines the study of how drugs affect our bodies (pharmacology) with the study of our genes and their functions (genomics). Allen will share his experience with pharmacogenomic research and discuss how OneOme’s RightMed® test can help physicians better target medications based on a patient’s individual genetics.
WHAT: OneOme participates in Minnesota Health Care Roundtable
Precision Medicine: A New Approach to Care
WHERE: Downtown Minneapolis Hilton and Towers – Symphony Room 2
1001 Marquette Ave., Minneapolis
WHEN: Thursday, April 20, 2017
1 – 4 p.m.
WHO: Josiah Allen, OneOme Director of Medical Affairs
Additional speakers from Ambry Genetics, Children’s Minnesota, Coverys, Medica, Mayo Clinic, Recombinetics
The OneOme RightMed pharmacogenomic test is an actionable, comprehensive test that helps personalize patients’ treatments, save time and money by eliminating the trial and error approach, reduce the risk of adverse drug reactions, and limit unintended drug-to-drug interactions. Co-developed with Mayo Clinic, the RightMed test covers over 340 drugs. The test is physician-ordered and produces an easy-to-read report along with access to the RightMed Advisor, an interactive solution for providers that categorizes drugs based on the patient’s DNA and helps guide prescription treatment decisions. By making prescriptions more personal, OneOme aims to address adverse drug reactions, which are the fourth leading cause of death in the United States.
Josiah Allen has considerable experience in personalized medicine, including clinical research, product development, and clinical adoption and implementation. Allen is an author of over a dozen peer-reviewed publications in pharmacogenomics, and he has lectured extensively on the clinical applications of pharmacogenomics. Prior to joining OneOme, Allen worked at the Mayo Clinic Department of Psychiatry and the Center for Individualized Medicine, and he was one of the founding members of Assurex Health. Allen earned his bachelor’s degree in psychology from Wheaton College and completed graduate work in molecular genetics and pharmacology at the University of Cincinnati.
Tomorrow’s event is the Minnesota Health Care Roundtable’s 47th Session. The biannual conference focuses on the future of healthcare and brings together panelists to share their insights on how to improve healthcare. For more information, please visit: mppub.com/MP_RT.html.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more, visit oneome.com.